Healthcare Review: Repligen, Rosetta Genomics, Alnylam Pharamaceuticals, Endo International, Biostar Pharmaceuticals Print E-mail
By Staff and Wire Reports   
Friday, 07 March 2014 02:42
U.S. stocks rose in early trading on Thursday, with the S&P 500 at a fresh record intraday high following upbeat labor market data, while traders kept an eye on developments in Ukraine. In a boost to riskier assets, the euro hit its highest against the U.S. dollar since late December after the European Central Bank kept interest rates on hold, shaking out bets of a cut in rates. Crimea's parliament voted on Thursday to join Russia and its Moscow-backed government set a referendum for March 16 on the decision, in an escalation of the crisis between Russia and the West over the Ukrainian Black Sea peninsula.

Shares of Repligen ($RGEN) take a dive in response to the company's earnings today. Shares initially plunged almost 16% in heavy volume before recovering a bit.Net income for 2013 grew 11% on a revenue increase of 9.5%.Guidance for 2014 includes revenues of $52M - $55M, 53% product gross margin, total income of $7M - $9M and year-end quick assets of $84M - $87M.Consensus estimates for 2014 are earnings of $.22/share on revenues of $53M.

Zacks Small Cap Research initiates coverage on Rosetta Genomics ($ROSG) with an Outperform rating. Analysts like the company's microRNA platform and establish a price target of $10.Shares currently exchange hands at $5.30.

China-based Biostar Pharmaceuticals ($BSPM +21.8%) signs a letter of intent with the Research Institute of Pharmaceuticals at Shaanxi University of Chinese Medicine to develop a drug for liver cancer based on Oleanolic Acid injection. Biostar's has found that the "AO" factor in Oleanic acid is "remarkably effective in killing the Hepatitis B virus, and it may also be used to kill cancer cells."

Alnylam Pharamaceuticals ($ALNY) finalizes its buy of Merck's ($MRK) Sirna Therapeutics that was previously disclosed on January 12.The total purchase price is $175M ($25M cash and $150M in ALNY common stock).The transaction represents a significant haircut for Merck considering the $1.1B cash price it paid for Sirna in 2006.

Endo International ($ENDP) treatment for adult men with hypogonadism, AVEED (testosterone undecanoate) injection, is now FDA-approved. The disease is associated with low levels or absence of the hormone testosterone. The product produces serum testosterone in the normal range by administering injections 4 weeks after the initiation of therapy and every 10 weeks thereafter. It will be commercially available this month.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter